Ilyang Pharmaceutical "COVID-19 Treatment Fails to Prove Efficacy in Russian Phase 3 Clinical Trial"
[Asia Economy Reporter Ji Yeon-jin] Ilyang Pharmaceutical announced on the 4th that it conducted a Phase 3 clinical trial with Russian R-Pharm for the treatment of COVID-19 using Radotinib, which is used as a treatment for chronic myeloid leukemia, but failed to demonstrate superior efficacy compared to the standard recommended treatment.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Trump Puts Iran Strike on Hold One Day Before Attack... "Full-Scale Offensive If Talks Fail"
- At 24°C It's Iced Coffee, at 31°C Tube Ice Cream... "It's Only May" But Convenience Stores Already Know: The 'Summer Boom' Thermometer
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Russian R-Pharm will not apply for marketing approval of Radotinib for the treatment of COVID-19 patients in Russia and plans to complete the registration of Radotinib for the indication of chronic myeloid leukemia within this year.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
